Celltrion Pharm Participates in International Liver Disease Conference "Liver Week 2026"

Sharing the Clinical Value of Vegzelma and Godeks
and Real-World Treatment Experience

Celltrion Pharm announced on the 16th that it participated in the international liver disease conference 'The Liver Week 2026' (hereafter referred to as Liver Week), held over three days from June 11 to 13 at Conrad Seoul in Yeongdeungpo-gu, Seoul, where it conducted academic presentations on 'Vegzelma' (ingredient: bevacizumab), a treatment for advanced liver cancer and metastatic colorectal cancer, and 'Godeks' (a combination drug containing orticarnitine and six other ingredients), a drug for liver diseases.

Celltrion Pharm participated in "The Liver Week 2026," an international conference on liver diseases held from the 11th to the 13th of this month at Conrad Seoul in Yeongdeungpo-gu, Seoul, where it conducted academic lectures focused on "Vegzelma," a treatment for advanced liver cancer and metastatic colorectal cancer, and "Godeks," a medication for liver diseases. Celltrion Pharm

During this year’s Liver Week, Celltrion Pharm organized a luncheon symposium and a breakfast forum focusing on Vegzelma and Godeks, respectively, sharing the clinical value of its products and real-world treatment experiences with healthcare professionals. In particular, the Vegzelma session centered on clinical results and real-world usage cases, highlighting both its potential for use in the field of liver disease treatment and the value of biosimilars.

Vegzelma is a biosimilar of bevacizumab and is approved for indications including metastatic colorectal cancer, epithelial ovarian cancer, primary peritoneal cancer, and cervical cancer. In addition, following the 2022 revision of reimbursement criteria announced by the Health Insurance Review and Assessment Service, the combination therapy of atezolizumab and bevacizumab is now included, making Vegzelma a major treatment option for patients with hepatocellular carcinoma.

The Vegzelma luncheon symposium, held on June 12, featured a lecture on the topic of 'Vegzelma and Celltrion's Biosimilars.' Professor Tak Wonyoung of Kyungpook National University School of Medicine served as the chair, while Professor Jung Sungwon of Ulsan University College of Medicine gave a presentation introducing the overview, definition, and advantages of biosimilars, as well as introducing Vegzelma and sharing real-world cases of its use in liver cancer with healthcare professionals.

On the same day, a breakfast forum on 'Godeks,' Celltrion Pharm’s flagship chemical product and a drug for liver diseases, was also held. Professor Chang Jaeyoung of Soonchunhyang University College of Medicine chaired the session, and Professor Lee Hana of Chung-Ang University College of Medicine gave a presentation titled 'Clinical Evidence and Hepatoprotective Effects of Carnitine,' sharing insights on changes in the liver disease treatment environment and real-world experiences with Godeks in medical practice.

A Celltrion Pharm representative stated, "This year’s Liver Week was a meaningful opportunity to share real-world clinical cases of Vegzelma and the academic evidence supporting Godeks for liver disease treatment with healthcare professionals. Moving forward, we will continue to promote the clinical value of each product at major conferences and strengthen communication with the medical field."

This content was produced with the assistance of AI translation services.